Thijs H. Oude Munnink

Author

University Medical Center Groningen ORCID

Also Known As

T H Oude Munnink, T. H. Oude Munnink, T. Oude Munnink, T.H. Oude Munnink, Thijs H Oude Munnink, Thijs H. Oude Munnink, Thijs Oude Munnink, Thijs H. Oude Munnink

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

University Medical Center Groningen University of Groningen Amsterdam UMC Location Vrije Universiteit Amsterdam Novartis (Switzerland)Target (United States)

About

Thijs H. Oude Munnink is an author at University Medical Center Groningen specializing in medicine, oncology, and radiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	300
2	Health Sciences	2	2	131
3	Cell Biology	2	2	142
4	Engineering	1	1	27
5	Immunology	1	1	118

Thijs H. Oude Munnink

Publications

Citations

H-Index

Page 1

	Year	Citations
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer Eli Dijkers, Thijs H. Oude Munnink, Jos G. W. Kosterink, Clinical Pharmacology & Therapeutics	2010	792
CXCR4 Inhibition with AMD3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy Urszula Domańska, Hetty Timmer‐Bosscha, Wouter B. Nagengast, Neoplasia	2012	185
Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake Marlous Arjaans, Thijs H. Oude Munnink, Sjoukje F. Oosting, Cancer Research Bevacizumab-induced NormalizationAngiogenesisBlood Vessel NormalizationMedicineBevacizumab Treatment	2013	118
89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients Sietske B.M. Gaykema, Carolien P. Schröder, Joanna Vitfell-Rasmussen, Clinical Cancer Research	2014	114
<sup>89</sup>Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922 Wouter B. Nagengast, Maarten A. de Korte, Thijs H. Oude Munnink, Journal of Nuclear Medicine	2010	112
<sup>89</sup>Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment Sjoukje F. Oosting, Adrienne H. Brouwers, Suzanne C. van Es, Journal of Nuclear Medicine	2014	111
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with <sup>89</sup>Zr-Fresolimumab PET Martha W. den Hollander, Frederike Bensch, Andor W.J.M. Glaudemans, Journal of Nuclear Medicine	2015	98
89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft Thijs H. Oude Munnink, Maarten A. de Korte, Wouter B. Nagengast, European Journal of Cancer MedicineHuman Tumour XenograftPathologyHsp90 Inhibitor Nvp-auy922Tumor Suppressor	2009	98
Everolimus Reduces <sup>89</sup>Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors Sophie J. van Asselt, Sjoukje F. Oosting, Adrienne H. Brouwers, Journal of Nuclear Medicine	2014	62
PET with the<sup>89</sup>Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models Thijs H. Oude Munnink, Marlous Arjaans, Hetty Timmer‐Bosscha, Journal of Nuclear Medicine	2011	54

Page 1